Drugs / LFB-R593
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00952575 | Aug 2009 → Jul 2011 | — | LFB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LFB-R593 | “A Phase II, Open-label, Randomised, Dose-finding Study to Compare the Efficacy (in Terms of Clearance of RhD-positive RBCs) and Safety of LFB-R593, a Monoclonal Anti-RhD...” NCT00952575 ↗ |
| Action | Deplete | “effectively eliminate exogenously-administered RhD-positive red blood cells from the circulation” NCT00952575 ↗ |
| Modality | Monoclonal antibody | “a Monoclonal Anti-RhD Antibody” NCT00952575 ↗ |